Annexin Pharmaceuticals AB (publ) has entered into an exclusive licence agreement with a U.S. University. The licence involves a novel therapeutic concept for treating cancer by administration of the Annexin A5 protein, functionally identical to Annexin Pharmaceuticals’ drug candidate ANXV. The licensing terms are according to industry standards.
Cirio's team consisted of Anders Burén (life science), Ulrica Salomon and Miranda Hermansson Varli (competition law).
For more information, please contact:
